Ontology highlight
ABSTRACT:
SUBMITTER: Gerlach D
PROVIDER: S-EPMC5955861 | biostudies-literature | 2018 May
REPOSITORIES: biostudies-literature
Gerlach Daniel D Tontsch-Grunt Ulrike U Baum Anke A Popow Johannes J Scharn Dirk D Hofmann Marco H MH Engelhardt Harald H Kaya Onur O Beck Janina J Schweifer Norbert N Gerstberger Thomas T Zuber Johannes J Savarese Fabio F Kraut Norbert N
Oncogene 20180301 20
Bromodomain and extra-terminal (BET) protein inhibitors have been reported as treatment options for acute myeloid leukemia (AML) in preclinical models and are currently being evaluated in clinical trials. This work presents a novel potent and selective BET inhibitor (BI 894999), which has recently entered clinical trials (NCT02516553). In preclinical studies, this compound is highly active in AML cell lines, primary patient samples, and xenografts. HEXIM1 is described as an excellent pharmacodyn ...[more]